Skip to main content
Fig. 4 | BMC Cancer

Fig. 4

From: Pre-clinical and clinical studies on the role of RBM3 in muscle-invasive bladder cancer: longitudinal expression, transcriptome-level effects and modulation of chemosensitivity

Fig. 4

RBM3 knockdown increases cell viability upon chemotherapy treatment in vitro. Viability of a RT4 and b T24 RBM3 siRNA silenced (black lines) and non-targeting siRNA control (grey lines) treated bladder cancer cells after exposure to increased doses of cisplatin and gemcitabine. Cells were treated in quadruplicate wells for 24 h (cisplatin) or 30 h (gemcitabine) and the viability was measured using WST-1. Differences in IC50 values between siRNA and negative control were calculated by non-linear regression of normalized values, relative to control (untreated cells, 100% cell viability). The graph represents one of three independent experiments. ***p < 0.001

Back to article page